D
Delbert Robinson
Researcher at North Shore-LIJ Health System
Publications - 87
Citations - 11875
Delbert Robinson is an academic researcher from North Shore-LIJ Health System. The author has contributed to research in topics: Schizophrenia & First episode. The author has an hindex of 46, co-authored 80 publications receiving 11116 citations. Previous affiliations of Delbert Robinson include Long Island Jewish Medical Center.
Papers
More filters
Journal ArticleDOI
Asymmetries of cortical shape: Effects of handedness, sex and schizophrenia
Katherine L. Narr,Robert M. Bilder,Eileen Luders,Paul M. Thompson,Roger P. Woods,Delbert Robinson,Philip R. Szeszko,Teodora Dimtcheva,Mala Gurbani,Arthur W. Toga +9 more
TL;DR: Although hemispheric shape asymmetries appeared less pronounced within female non-dextrals, asymmetry indices were not shown to differ significantly across sex, hand preference or diagnosis, or to reveal interactions of handedness with sex or diagnosis.
Journal ArticleDOI
Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia.
Todd Lencz,Robert M. Bilder,Elihu Turkel,Robert Goldman,Delbert Robinson,John M. Kane,Jeffrey A. Lieberman +6 more
TL;DR: Deficits in both domains of WM suggest abnormality in the posterior and prefrontal cortexes and are present even in unmedicated patients in the first episode of illness.
Journal ArticleDOI
A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes
Delbert Robinson,Juan A. Gallego,Majnu John,Georgios Petrides,Youssef Hassoun,Jian-Ping Zhang,Leonardo V. Lopez,Raphael J. Braga,Serge Sevy,Jean Addington,Charles H. Kellner,Mauricio Tohen,Melissa Naraine,Natasha Bennett,Jessica Greenberg,Todd Lencz,Christoph U. Correll,John M. Kane,Anil K. Malhotra +18 more
TL;DR: Overall, if the potential for akathisia is a concern, low-dose risperidone as used in this trial maybe a preferred choice over aripiprazole, but aripIPrazole would be the preferred choice in most situations based upon metabolic outcome advantages and some symptom advantages within the context of similar positive symptom response between medications.
Journal ArticleDOI
Subject selection biases in clinical trials : Data from a multicenter schizophrenia treatment study
TL;DR: To evaluate subject selection biases in clinical trials, demographic characteristics of subjects at different phases of evaluation for a multicenter maintenance trial in schizophrenia were examined and showed that selection biases would rarely change overall study outcomes to a clinically relevant degree.
Journal ArticleDOI
DRD2 Promoter Region Variation Predicts Antipsychotic-Induced Weight Gain in First Episode Schizophrenia
Todd Lencz,Delbert Robinson,Barbara Napolitano,Serge Sevy,John M. Kane,David Goldman,Anil K. Malhotra +6 more
TL;DR: The relationship between -141C Ins/Del (rs1799732), a functional promoter region polymorphism in DRD2, and antipsychotic-induced weight gain in first episode schizophrenia patients enrolled in a randomized trial of risperidone versus olanzapine was examined.